CAJ | 학술논문

目的评估伊班膦酸钠对腹膜透析骨质疏松患者的疗效和安全性.方法采用自身前后对照方法分别检测腹膜透析骨质疏松患者的股骨颈骨密度、生化及营养指标,比较治疗前、后各指标变化.结果治疗后股骨颈骨密度明显增加,差异有统计学意义(T值-2.65±0.5比-2.97±0.5,P＜0.05,Z值-1.88±0.67比-2.02±0.58,P＜0.05).体质量指数,前白蛋白,白蛋白也明显增加,血钙、血磷、碱性磷酸酶、iPTH和Kt/V无明显变化.未发现严重不良反应.结论短期应用伊班膦酸钠能改善腹膜透析患者骨质疏松,且耐受性好.
목적 평고이반련산납대복막투석골질소송환자적료효화안전성.방법 채용자신전후대조방법분별검측복막투석골질소송환자적고골경골밀도、생화급영양지표,비교치료전、후각지표변화.결과 치료후고골경골밀도명현증가,차이유통계학의의(T치-2.65±0.5비-2.97±0.5,P＜0.05,Z치-1.88±0.67비-2.02±0.58,P＜0.05).체질량지수,전백단백,백단백야명현증가,혈개、혈린、감성린산매、iPTH화Kt/V무명현변화.미발현엄중불량반응.결론 단기응용이반련산납능개선복막투석환자골질소송,차내수성호.
Objective To assess the efficacy and safety of ibandronate in peritoneal dialysis patients with osteoporosis.Methods In this self-controlled study,the changes in bone mineral density (BMD) of the femoral neck measured by dual energy X-ray absorptiometry,biochemistry and nutritional indices were determined before and after ibandronate treatment in peritoneal dialysis patients.Results The treatment of ibandronate resulted in substantially increased BMD [T =-2.65±0.5 vs-2.97±0.5,P ＜ 0.05; Z=-1.88±0.67 vs-2.02±0.58,P ＜ 0.05].There was a pronounced increase in the body-mass index and the levels of prealbumin and albumin.The pre-and post-treatment difference in serum calcium,serum phosphate,bone alkaline phosphate,iPTH and Kt/V was unremarkable.No serious adverse event was reported.Conclusion Short-term treatment with ibandronate may ameliorate osteoporosis and can be well tolerated in peritoneal dialysis patients.